# A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients

> **NCT01506947** · PHASE4 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 65 (actual)

## Conditions studied

- Moderate to Severe Secondary Hyperparathyroidism
- Stage 5 Chronic Kidney Diseases

## Interventions

- **DRUG:** Paricalcitol
- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT01506947
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-10
- **Primary completion:** 2016-04-07
- **Final completion:** 2016-04-07
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01506947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01506947, "A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01506947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*